Fig. 6
MiR-143 inhibits the carcinogenic effect of MSI2 in vivo (A) BALB/c-Nu mice were subcutaneously inoculated with 5 × 106 MSI2-OE. HEL cells or NC. HEL cells to establish xenograft AML model, and then treated intratumorally with micrOFFTM agomir-143 or agomir-NC. Tumor volumes from each group of mice were recorded regularly, N = 7. (B) Tumors from four groups of mice were presented respectively, N = 7. (C) Tumor weights were recorded, N = 7. (D–F) Spleens and livers from four groups of mice were presented (D), and spleen weight (E) and liver weight (F) were measured, N = 4. (G) Representative Wright-Giemsa staining of bone marrow cells from each group of mice at the end point, scale bar = 20 μm. (H) Proportion of bone marrow cells, including blasts, differentiating myeloids/monocytes, differentiated myeloids/monocytes and lymphocytes. (I) Relative MFI of CD45, CD36 and CD235a in bone marrow (left panel) and spleen (right panel) from each group of mice. (J) Expression of CD45 in spleen from each group of mice was detected by IHC. Data are expressed as mean ± SD (error bars). * P < 0.05, ** P < 0.01 and ***P < 0.001, t-test